• Explore /
  • Poster
  • / A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.

A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.

Abstract Poster

Authors

null

James J. Harding

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

James J. Harding, Amita Patnaik, Victor Moreno, Mark Stein, Anna M. Jankowska, Nieves Velez de Mendizabal, Zhuqing Tina Liu, Mythili Koneru, Emiliano Calvo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT03099109

Citation

J Clin Oncol 37, 2019 (suppl 8; abstr 12)

DOI

10.1200/JCO.2019.37.8_suppl.12

Abstract #

12

Poster Bd #

A2

Abstract Disclosures

Similar Posters

First Author: Ye Guo

First Author: Francisco Robert

First Author: John Ebben

First Author: Judy S. Wang